Specialized Working Group on Immune Therapies for Hematologic Disorders
Overview
A critical step towards prevention, cure and improved quality of life has been progress in the treatment of hematological and solid malignancies. Treatment has been revolutionized by the introduction of novel immunotherapeutic strategies.
Patients suffering from malignancies that seemed to be untreatable now experience long-term disease control with novel immunotherapies such as:
- Immune check point inhibitors
- T-cell redirected strategies (CAR T-cells, TCR transduced T cells, bispecific antibodies)
Great advances have been made in applying immunotherapies and understanding their modes of action. However, there are still new and persistent challenges in daily practice that need to be overcome. Patients show primary and acquired resistance discrepancy in clinical and radiological benefit, as well as life-threatening adverse events.
The ITHD SWG’s mission is to overcome these challenges by taking an integrative and multidisciplinary approach. We provide a platform that combines patient care, research, outreach, training and education to foster clinical and translational studies with rapid transition into patient benefit.
Join us
If you work in our field and share our mission to advance our understanding of ITHD, you’d be welcome to join our SWG. However, before you apply, we recommend you read our application guidance.
Ready? Apply now on the EHA Portal.
Apply to join this SWGIf you have any questions, please email our SWGs team.